The first phase of B.C.’s precedent-setting Biosimilars Initiative appears to have gone smoothly, yet claims data indicate that less than half of affected patients actually made the switch. Meanwhile, Alberta launches its own biosimilar switching program.
In the last 10 years, we haven't made substantial progress improving access to palliative care for Canadians; we wouldn't tolerate that in other areas of medicine